Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Date:5/15/2008

from $5.7 million in the same period last year. The decrease was due primarily to restructuring of personnel and reduced general and administrative expenses.

The Company's net loss for the first quarter of 2008 was $4.8 million, compared to $6.0 million for the same period in 2007. Basic and diluted net loss for the first quarter of 2008 was $0.76 per share based on 6.38 million total shares outstanding, compared to a basic and diluted net loss of $1.54 per share based on 3.92 million total shares outstanding for the same period in 2007. Earnings per share calculations are on a post reverse stock split basis.

At March 31, 2008, the Company's cash, short- and long-term investments totaled $14.3 million, compared to $20.4 million at December 31, 2007. Net cash used in operating activities in the first quarter of 2008 was $5.5 million. The semi-annual payment of interest of approximately $0.6 million on the senior convertible note is due during the first and third quarters, which results in higher net cash outflows for these quarters. Vermillion continues to diligently manage expenses and cash utilization.

Recent Highlights and Accomplishments

During the first and into the second quarter of the year, Vermillion achieved numerous milestones in its three leading diagnostic programs and continued to progress in its corporate development efforts.

-- PAD Diagnostic Program

* Established a clinical steering committee to provide advice on

studies to support registration of VASCLIR with the FDA and to

further potential market adoption.

* Presented data from a study providing further confirmation that the

Company's test may aid in the diagnosis of PAD. The research, which

was presented at the American College of Cardiology 57th Annual

Scientific Session, suggests that such a test may be useful in

helping determine a patient's risk for de
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Mississauga, Ontario (PRWEB) May 21, 2013 ... expert scientists of the ITN to design the ... usefulness of two key clinical models used in ... Chamber (EEC) and Nasal Allergen Challenge (NAC) models. ... supported by numerous publications, to date no direct ...
(Date:5/21/2013)... May 21, 2013 PathoGenetix, Inc., a ... strain typing, announced today that it has successfully identified ... coli strains obtained from the Centers for Disease Control ... (GSS™) technology. The findings are detailed in a ... American Society for Microbiology in Denver on Monday. , ...
(Date:5/20/2013)... Al Khaimah, UAE (PRWEB) May 21, 2013 ... private equity consultancy specializing in “game-changing” life science and ... of Ms. Dalia Dergham to its International Project Team. ... to bring even greater multi-cultural depth to Grace Century ... projects around the globe. , Ms. Dergham holds both ...
(Date:5/20/2013)... May 20, 2013  (PSHR) Pacific Shore Holdings, ... products across a broad range of product categories ... investor relations firm, BlueWater Advisory Group, to provide ... trading process, and to direct the company,s outreach ... Matthew Mills , Pacific ...
Breaking Biology Technology:Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Pacific Shore Holdings Retains Investor Relations Firm 2
... 11 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ... due to the technical difficulties encountered on,today,s conference ... tomorrow,Wednesday, November 12, 2008. On this call, BMP ... since technical difficulties prevented the,Company from addressing all ...
... Rapid Detection Flu A+B Test Differentiates Flu Strains A ... 20 percent of the U.S. population becomes ill with ... bacterial infections,present similarly to influenza. Because of this, overuse ... to the growing problem of,antibiotic resistance., This flu ...
... Contamination by an unknown,organism often calls for ... organism can be identified and eliminated. Such ... and productivity of medical device,and pharmaceutical manufacturers ... Microbial ID Breakthrough: How DNA Sequencing,Services Help ...
Cached Biology Technology:BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 2BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 3MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season 2White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers 2White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers 3
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... alter the way genes function without changing the ... the blood of pregnant women during any trimester, ... in the weeks after giving birth, and an ... The findings of the small study involving 52 ... Molecular Psychiatry . , "Postpartum depression can ...
(Date:5/20/2013)... Bacteria resistant to the antibiotic colistin are also ... human body, according to a study in ... American Society for Microbiology. Cross-resistance to colistin and ... the body against bacterial attack, could mean that ... saddled with a crippled immune response. Colistin is ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... have recovered fossils of a 60-million-year-old South American snake whose ... seem a bit cuter and more cuddly. Named ... snake,s vertebrae suggest it weighed 1140 kg (2,500 pounds) and ... report describing the find appears in this week,s Nature ...
... University of Michigan scientists report highly encouraging evidence that ... other microbes, may be able to quell the ravaging, ... deaths. Cystic fibrosis is an inherited chronic ... the United States. Patients have mucus-clogged lungs that leave ...
... TALLAHASSEE, Fla. -- The facial structure of an ancient ... them to eat large, hard nuts and seeds as ... study by an international team of researchers that includes ... published in the journal Proceedings of the National ...
Cached Biology News:Largest prehistoric snake on record discovered in Colombia 2Largest prehistoric snake on record discovered in Colombia 3Nanoemulsion potent against superbugs that kill cystic fibrosis patients 2Nanoemulsion potent against superbugs that kill cystic fibrosis patients 3
...
... The product contains 5 ml of DETACHaBEAD ... release mouse CD4+ T cells from Dynabeads ... mosue CD4+ T cells from Dynabeads Mouse ... cells are suitable for any downstream application ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Porcine IFN-gamma ELISpot Development Module...
Biology Products: